UK markets closed
NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.74 (-0.93%) GOLD FUTURES
2,427.70 -10.80 (-0.44%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,527.16 -694.09 (-1.26%)
Evolus, Inc. (EOLS)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 13.42 |
| Open | 13.38 |
| Bid | 13.14 x 200 |
| Ask | 13.22 x 100 |
| Day's range | 13.05 - 13.49 |
| 52-week range | 7.07 - 15.43 |
| Volume | |
| Avg. volume | 645,079 |
| Market cap | 823.954M |
| Beta (5Y monthly) | 1.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.04 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.29 |
ZacksEvolus (EOLS) Releases Favorable Dermal Fillers Study Data
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
Business WireEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
NEWPORT BEACH, Calif., May 20, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville.
GuruFocus.comDirector David Gill Sells 10,361 Shares of Evolus Inc (EOLS)
On May 14, 2024, David Gill, Director at Evolus Inc (NASDAQ:EOLS), executed a sale of 10,361 shares of the company.
© 2024 Yahoo. All rights reserved.